May 2, 2012

French animal health company, Merial reports sales of EUR578 million (US$765 million)), down by 5.4%, impacted by a tough comparable first quarter 2011.

Sales of the animal health company in emerging markets grew 6.0% to €124 million.

Sales of the production animals segment were down by 3.7%, reflecting decreased sales of the veterinary public health segment which benefited from one-off sales of Foot-and-Mouth Disease (FMD) and bluetongue virus vaccines in the first quarter of 2011.

Excluding sales of FMD and bluetongue virus vaccines, sales of the production animals segment were up 5.4%. The ruminant segment continued to deliver strong growth (up 9.8%) driven by the recent launch in the US of the antibiotic, Zactran, against bovine respiratory disease. The avian segment grew by 5.4%, led by the vaccine Vaxxitek.

Sales of the companion animals segment reached EUR398 million (US$526 million), down 6.1%.

In March, Merial acquired Newport Laboratories, a US privately held company, which is a leader in autogenous vaccines with a focus on swine and bovine production markets. Merial is part of the Sanofi group, which reached EUR8.5 billion (US$11.3 billion) in sales in the first quarter of 2012. This is a 7.0% on-year increase.